ADC Therapeutics FY 2025 license revenues and royalties jumped 401% to USD 7.81 million

Reuters

Mar 10

ADC <a href="https://laohu8.com/S/LENZ">Therapeutics</a> FY 2025 license revenues and royalties jumped 401% to USD 7.81 million

ADC Therapeutics reported Q4 net product revenue of USD 22.31 million, up 36%, citing variability in customer ordering with underlying demand broadly stable. FY net product revenue was USD 73.55 million, up 6%, driven by higher selling price and relatively flat volume year over year. Q4 net loss narrowed to USD 6.41 million, while FY net loss was USD 142.62 million. FY license revenues and royalties were USD 7.81 million, up more than quadrupled. Cash and cash equivalents totaled USD 261.34 million at year-end, and management said it expects LOTIS-5 Phase 3 topline data in Q2 2026 with full LOTIS-5 and LOTIS-7 data by year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603100730PR_NEWS_USPR_____NY05567) on March 10, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2618937924"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618937924\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618937924?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 19:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618937924","market":"us","top_or_hot":-1,"title":"ADC Therapeutics FY 2025 license revenues and royalties jumped 401% to USD 7.81 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ADC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY 2025 license revenues and royalties jumped 401% to USD 7.81 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ADC Therapeutics reported Q4 net product revenue of USD 22.31 million, up 36%, citing variability in customer ordering with underlying demand broadly stable. FY net product revenue was USD 73.55 million, up 6%, driven by higher selling price and relatively flat volume year over year. Q4 net loss narrowed to USD 6.41 million, while FY net loss was USD 142.62 million. FY license revenues and royalties were USD 7.81 million, up more than quadrupled. Cash and cash equivalents totaled USD 261.34 million at year-end, and management said it expects LOTIS-5 Phase 3 topline data in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026 with full LOTIS-5 and LOTIS-7 data by year-end 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ADCT\">ADC Therapeutics SA</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603100730PR_NEWS_USPR_____NY05567) on March 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ADC Therapeutics FY 2025 license revenues and royalties jumped 401% to USD 7.81 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nADC Therapeutics FY 2025 license revenues and royalties jumped 401% to USD 7.81 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-10 19:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ADC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY 2025 license revenues and royalties jumped 401% to USD 7.81 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ADC Therapeutics reported Q4 net product revenue of USD 22.31 million, up 36%, citing variability in customer ordering with underlying demand broadly stable. FY net product revenue was USD 73.55 million, up 6%, driven by higher selling price and relatively flat volume year over year. Q4 net loss narrowed to USD 6.41 million, while FY net loss was USD 142.62 million. FY license revenues and royalties were USD 7.81 million, up more than quadrupled. Cash and cash equivalents totaled USD 261.34 million at year-end, and management said it expects LOTIS-5 Phase 3 topline data in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026 with full LOTIS-5 and LOTIS-7 data by year-end 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ADCT\">ADC Therapeutics SA</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603100730PR_NEWS_USPR_____NY05567) on March 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL843JP6:1","article_id":"2618937924","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618937924","pubTimestamp":1773143569,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ADC Therapeutics reported Q4 net product revenue of USD 22.31 million, up 36%, citing variability in customer ordering with underlying demand broadly stable. FY net product revenue was USD 73.55 million, up 6%, driven by higher selling price and relatively flat volume year over year. Q4 net loss narrowed to USD 6.41 million, while FY net loss was USD 142.62 million. FY license revenues and royalties were USD 7.81 million, up more than quadrupled. Cash and cash equivalents totaled USD 261.34 million at year-end, and management said it expects LOTIS-5 Phase 3 topline data in Q2 2026 with full LOTIS-5 and LOTIS-7 data by year-end 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4505":"高瓴资本持仓","ADCT":"ADC Therapeutics SA"},"translate_title":"ADC Therapeutics 2025财年许可收入和特许权使用费增长401%至781万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADCT":0.9},"content_text":"ADC Therapeutics FY 2025 license revenues and royalties jumped 401% to USD 7.81 million\n    \n\n        ADC Therapeutics reported Q4 net product revenue of USD 22.31 million, up 36%, citing variability in customer ordering with underlying demand broadly stable. FY net product revenue was USD 73.55 million, up 6%, driven by higher selling price and relatively flat volume year over year. Q4 net loss narrowed to USD 6.41 million, while FY net loss was USD 142.62 million. FY license revenues and royalties were USD 7.81 million, up more than quadrupled. Cash and cash equivalents totaled USD 261.34 million at year-end, and management said it expects LOTIS-5 Phase 3 topline data in Q2 2026 with full LOTIS-5 and LOTIS-7 data by year-end 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603100730PR_NEWS_USPR_____NY05567) on March 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}